INTRODUCTION 1
Leishmania parasites are the etiological agents of the leishmaniases. The parasites are transmitted to 2 mammals including humans by the bite of phlebotomine sand flies and, occasionally, by sharing of needles, 3 blood transfusion and congenital transmission [18] . In terms of global burden of disease, the leishmaniases 4 are the third most important vector-borne disease and it is estimated that world-wide there are an annual 1.5-5 2 million cases, with up to 350 million people at risk of infection and disease. 6
Surveillance data indicate that the global number of cases has increased in recent decades and 7 several important epidemics have been reported (e.g. Sudan and Afghanistan). Such increases can be 8 explained, in part, by improved diagnosis and case notification, but are also due to other factors: inadequate 9 vector or reservoir control; increased detection of disease associated with opportunistic infections (e.g. 10 HIV/AIDS); urbanization and deforestation; emergence of anti-leishmanial drug resistance; economic 11 hardship; armed conflict and tourism. Particularly, the latter two have lead to the increasing observation and 12
management of leishmaniasis patients in clinical practices of traditionally non-endemic areas in North 13
America and Northern Europe. Thus, more than 600 U.S. soldiers contracted leishmaniasis in Iraq since 14
2003, most of which were diagnosed and treated at the Walter Read Army Medical Center in Washington 15 D.C. [28] . Similarly, in the U.K. the number of travellers with leishmaniasis seen by the Hospital of Tropical 16
Diseases in London has more than quadrupled in the past 10 years [13] . Here we critically review current 17 molecular approaches for leishmaniasis diagnosis, primarly focusing on the detection of human disease 18 rather than their applications in the veterinary field. 19 
20

CLINICAL PATHOLOGY 21
The reason why the leishmaniases are such a diagnostic challenge is because of the wide spectrum 22
of clinical manifestations that they may present: ulcerative skin lesions developing at the site of the sand fly 23 bite (localised cutaneous leishmaniasis, LCL); multiple non-ulcerative nodules (diffuse cutaneous 24 leishmaniasis, DCL); destructive mucosal inflammation (mucosal leishmaniasis, ML); and disseminated, 25 potentially fatal, visceral infection (visceral leishmaniasis, VL) [18] . These main manifestations may 26 themselves deviate, complicating definitive clinical diagnosis even further. Cutaneous leishmaniasis (CL) 27
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Several serological approaches are commonly used in VL diagnosis. In particular, freeze-dried 4 antigen based direct agglutination tests and commercially available immunochromatographic dipstick tests 5 have increasingly become reference tests in operational settings, as they are of great sensitivity and 6 specificity [3], easy to use, and require minimal technological expertise or laboratory setup. Serological tests 7 are rarely used in CL diagnosis, because sensitivity can be variable and because the number of circulating 8 antibodies against CL-causing parasites tends to be low (e.g. if previous chemotherapy has been 9 administered). Specificity can also be variable, especially in areas where cross-reacting parasites (e.g. 10
Trypanosoma cruzi) are prevalent. 11
The Montenegro skin test (MST) is occasionally used in CL diagnosis (e.g. in epidemiological 12 surveys and vaccine studies), because of its simple use and because of its high sensitivity and specificity 13
[26]. The main disadvantage of the MST is that it does require culture facilities to produce the MST antigen, 14 that different antigen preparations impact test sensitivity, and that the test does not distinguish between past 15 and present infections. The MST is not used for VL diagnosis, as patients only develop strong Leishmania-16 specific cell-mediated immunity when cured [1] . 17
18
MOLECULAR DIAGNOSIS 19
The Available Molecular Approaches 20
Albeit different molecular methods have successively been evaluated for leishmaniasis diagnosis 21 (e.g. pulse field gel and multilocus enzyme electrophoresis), PCR-based assays currently constitute the main 22 molecular diagnostic approach of researchers and health professionals. Several distinct PCR formats are 23 available which may broadly be classified into 'mid-tech', 'high-tech' and 'low-tech' approaches. 'Mid-24 tech' approaches are probably the most widely used and comprise conventional PCR assays, in which PCR performed with a single all-in set-up and detection of fluorescence is done within a closed tube, decreasing 7 the risk of laboratory contamination by amplicons. Applications are rapid and of high-throughput, but 8 equipment is comparatively expensive and working costs remain high (e.g. according to our own own 9 estimation at the Instituut voor Tropische Geneeskunde, Antwerp the cost per sample analyzed is US$ 12 for 10 FRET-based assays vs. US$ 2.5 for PCR-RFLP). 'Low-tech' approaches refer to simplified PCR methods 11 for use in laboratory settings with minimal equipment. Simplification can potentially be done at the two 12 main steps of the PCR protocol: target amplification and detection of the PCR products. Loop-mediated 13 isothermal amplification (LAMP) represents a promising avenue for both steps: it requires only a simple 14 water bath for amplification and detection can be done visually by using SYBR-Green I dye, which turns 15 green in the presence of amplified products and remains orange in its absence. The method was claimed to 16 be 100 times more sensitive than conventional PCR in the detection of Trypanosoma brucei [11] , but so far, 17 this has -to our knowledge-not been applied to leishmaniasis diagnosis yet. Simplification of detection has 18 been attempted by PCR-ELISA, a 'reverse hybridization' method based on the capture of PCR amplicons by 19 specific probes immobilized in ELISA microtitre wells and colorimetric visualization [6] . High sensitivity 20 was observed in blood samples from HIV-negative VL patients [6] . However, in PCR-ELISA, detection is 21 still dependent on sophisticated equipment (i.e. an ELISA-plate reader). More recent methods such as 22
oligochromatography-PCR (OC-PCR [5]) represent a more promising alternative. This method requires a 23
PCR-cycler and a waterbath, and PCR products are visualized in 5 minutes on a dipstick through 24 hybridization with a gold-conjugated probe; an additional advantage is that internal PCR controls can be 25 placed onto the dipstick. Phase I-evaluation of a first OC-PCR prototype for the diagnosis of sleeping 26 sickness revealed 100% sensitivity and specificity [5]; a similar prototype is currently under evaluation for 27 the diagnosis of leishmaniasis (see http://www.tryleidiag.org). Combination of concepts like LAMP and OC 28
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Practical Applications of Molecular Methods in Leishmaniasis Diagnostics 4
In terms of practical applications, six main clinical and/or biological questions may be answered by 5 nucleic-acid based methods to diagnose leishmaniasis. 6
First, PCR allows a highly sensitive and specific (up to 100%) detection of the Leishmania parasite 7 irrespective of species or genus. This application is required for differential diagnosis before initiating 8 therapy and the performances of PCR have consistently been shown to be higher than microscopy or parasite 9 culture, particularly in samples with low parasite loads (e.g. in MCL patients [9] or in samples from less 10 intrusive sources, such as blood [4] and conjunctiva [24] ). The contribution of PCR also appears to be 11 particularly relevant for diagnosis of leishmaniasis in patients co-infected with HIV [2, 4, 6] . Parasite 12 detection by PCR for confirmation of clinical cure appears to be important in VL [17] , but should be further 13 explored in CL as up to 80% of patient scars remain PCR positive, even 8 years after their clinical cure [22] . 14 Secondly, host tissue quantification of parasites might be assessed by PCR. This may be highly 15 relevant for monitoring disease progression and outcome of anti-leishmanial therapy, e.g. for the clinical 16 management of HIV-coinfected patients [2] and those cured CL patients at risk of developing MCL [17] . For 17 such application, protocols of real-time quantitative PCR amplification of DNA have been developed, which 18 reportedly have high analytical sensitivity (0.0125 parasites per ml blood) and excellent linearity [14] . 19
Thirdly, for some applications, it might be necessary to demonstrate the viability of the detected 20 parasites, e.g. when assessing the efficacy of drug therapies and predicting treatment outcomes. In this case, 21
RNA should be preferred to DNA as an amplification target, because the latter is still detected for a long 22 Fifthly, molecular diagnosis might allow defining parasite-specific features such as virulence or 11 drug resistance. This application is still being explored as it requires identifying robust markers of the 12 corresponding phenotypes (not yet available), but it might be relevant in the future for the prognosis or 13 determination of the most adequate treatment or identification of those patients at risk of ML. 14 Sixthly, highly discriminatory fingerprinting tools might be useful for so-called 'parasite tracking'. 15
Such application is probably more relevant for epidemiological purposes than for diagnosis (e.g. in outbreak 16 investigations or tracking of drug-resistant parasite strains). The best illustration of the performances of 17 fingerprinting comes from the work of Cruz et al [4] who analyzed kinetoplast DNA RFLP patterns of 18 Leishmania parasites in syringes discarded by intravenous drug users (IVDUs), demonstrating that syringe 19 sharing can indeed promote the spread of Leishmania clones among IVDUs. 20
In real life, these six molecular applications will be implemented depending on several criteria 21 including the clinical relevance of the corresponding hypothesis to be answered, the availability of 22 alternative methods, the technical skills of the personnel and/or the extent of the laboratory set-up. For 23 example, for simple parasite detection in clinical laboratories of non-endemic countries the trend is to prefer 24 molecular diagnosis, because microscopists with extensive experience in detecting amastigotes in 25 microscopy slides are usually not available and laboratory facilities are well equipped. In contrast, in 26 endemic countries, where microscopists's skills are maintained due to routine laboratory practice, 27
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Operational Aspects 4
The choice of a specific PCR assay and approach will depend of two main criteria. On one hand, 5 high throughput applications (e.g. central reference laboratories or epidemic outbreak investigations) would 6 require methods such as real-time PCR or PCR-ELISA, while single test applications (e.g. peripheral or 7 travel medicine laboratories) could be done with other assays (e.g. oligochromatography). On the other 8 hand, according to the local infrastructure, training and budget, low-tech assays could be preferred to high-9 tech ones, when available ( Table 1) . 10
Clearly, the applicability of PCR in the 6 approaches outlined above depends on the existence of 11 adequate genetic markers. For detection, quantification and viability studies, where sensitivity must be 12 maximized, high copy number targets are chosen (e.g. ribosomal DNA genes, kinetoplast DNA minicircles, 13 Table 1) . Findings of these comparative studies might differ from one report to another: for example, 26 whereas one study indicated a higher sensitivity of kinetoplast DNA-based assays [1]), another reported a 27
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on September 23, 2017 by guest http://jcm.asm.org/ Downloaded from similar sensitivity to those based on ribosomal DNA amplification [26] . Comparison between studies should 1 be done with extreme care, taking into consideration (i) the clinical context of the study and (ii) the clinical 2 and laboratory criteria used for defining cases and non cases. In the absence of a real gold standard for 3 diagnosis of leishmaniasis, this may have important consequences for the definitions of sensitivity and 4 specificity. Comparative studies of protocols should be encouraged and updated to the latest technological 5 developments in the field, and, most importantly, should be done as multi-center studies with adequate 6 sample sizes to allow for statistical comparisons of evaluated diagnostic protocols. Samples and protocols 7 should be exchanged, same case definitions for determination of sensitivity and specificity should be used, 8
protocol of cost-effectiveness should be determined, and standard operating procedures should be 9 recommended (see report of an expert group: http:// www.leishmed.net). 10
11
CONCLUSION AND FUTURE PERSPECTIVES 12
PCR-based protocols have increased the speed and sensitivity of species-specific leishmaniasis 13 diagnosis compared to the conventional techniques such as microscopy and parasite culture. However, PCR-14 based protocols urgently need standardization and optimization. Recommendations include usage of 15 extraction controls, internal controls, a Leishmania standard control, replicate assays and participation in an 16 external quality control program. Compared to other diagnostic techniques available, molecular approaches 17 remain expensive and require technological expertise, and efforts should be made to make PCR platforms 18 more user-friendly and cost-effective, especially in remote leishmaniasis-endemic areas. 19
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General Comments
A myriad of PCR protocols to detect Leishmania DNA in clinical samples have been developed. Depending on laboratory setup, origin of clinical samples, sample storage and processing, DNA extraction protocol, choice of PCR primers and PCR methodology protocols can vary considerably in sensitivity and specificity. One of the main drawbacks of research to date has been the absence of multi-center studies evaluating PCR protocols for leishmaniasis diagnosis. Most of the diagnostic PCR protocols for leishmaniasis are not validated "in-house" protocols, also known as "home -brew" assays. Only one, a protocol developed by the Walter Reed Army Institute of Research (WRAIR) based on the original work of Wortmann et al. [26] is approved by the College of American Pathology (CAP), with the WRAIR laboratory becoming CAP certified for leishmaniasis diagnosis using this specific protocol. A new, "second generation" assay using a dry down bead format and performed on Smartcycler technology [http://www.cepheid.com] is currently being validated in support of an FDA application expected in early 2007 (A Magill, pers communication). Sample Collection PCR protocols to detect Leishmania DNA have used a variety of samples including lesion biopsies, scrapings, imprints, smears, exudates and aspirates (CL and ML diagnosis); spleen, lymph node and bone marrow aspirates (mainly in VL diagnosis); conjunctival swabs and aspirates (VL diagnosis); whole blood, buffy coat and serum (VL, CL and ML diagnosis). Samples should be taken in duplicate.
Sample Transport
Depending on sample material, samples have to be used fresh, or can be collected in tubes, on filter paper or slides, sometimes requiring the addition of reagents (e.g. buffers) to stabilize the materials. If not used fresh, samples collected in the field have to be stored accordingly, usually on ice and then at 4 o C or -20 o C; long-term storage should be done at -40 o C and below.
Pretreatment of Samples
Prior to DNA extraction, several methods are available to increase DNA yield and the probability of detecting pathogen DNA in a clinical sample, including sonication, incubation with proteinases and lysis using a range of buffers.
DNA Extraction
Standard DNA extraction protocols include the use of phenol-chlorofom, Chelex resin or silica. Several commercial DNA kits have been used successfully to extract Leishmania DNA from clinical samples. Extracted DNA may have to be diluted in water prior to amplification in order to prevent PCR inhibition.
Choice of PCR Primers and Platform
Over the years several PCR primers have become available and target either the kinetoplast or ribosomal DNA, internal transcribed spacers, mini-exon genes, specific gene sequences (e.g. glycoproteins, heat shock proteins, cysteine proteinases), Primers can be either genus, subgenus or species-specific. A range of PCR platforms and approaches exist, which have been described in the manuscript text.
Additional Steps
Once amplified, the conventional approach has been to visualize PCR amplification products on ethidium bromide-stained agarose gels under ultraviolet light. Platforms that do not require that step are becoming increasingly used, e.g. real-time PCR [26] or oligochromatographic PCR [5] . The sensivity and specificity of most protocols can be significantly increased by hybridization to genus or speciesspecific probes. Originally these probes were labeled with radioactive isotopes, but are now commonly labeled with fluorescent dyes. Specificity of protocols can also be increased by cleaving PCR amplification products with restriction enzymes, yielding species and strain-specific restriction patterns that can be visualized after electrophoresis. Standardization All PCR assays should have, at least, DNA extraction controls (i.e. naïve samples spiked with known amounts of pathogen DNA as well as a sample with water) [20], internal amplification controls (i.e. host DNA), negative and positive in-run controls; replicate asssays should be carried out. Laboratories should also allow for a mechanism of external quality control.
